These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29857275)

  • 1. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
    Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
    Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural optimization on a virtual screening hit of smoothened receptor.
    Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
    Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
    Ma H; Lu W; Sun Z; Luo L; Geng D; Yang Z; Li E; Zheng J; Wang M; Zhang H; Yang S; Zhang X
    Eur J Med Chem; 2015 Jan; 89():721-32. PubMed ID: 25462278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for allosteric interactions of antagonist binding to the smoothened receptor.
    Rominger CM; Bee WL; Copeland RA; Davenport EA; Gilmartin A; Gontarek R; Hornberger KR; Kallal LA; Lai Z; Lawrie K; Lu Q; McMillan L; Truong M; Tummino PJ; Turunen B; Will M; Zuercher WJ; Rominger DH
    J Pharmacol Exp Ther; 2009 Jun; 329(3):995-1005. PubMed ID: 19304771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and mechanism of action of the acylguanidine MRT-83, a novel potent Smoothened antagonist.
    Roudaut H; Traiffort E; Gorojankina T; Vincent L; Faure H; Schoenfelder A; Mann A; Manetti F; Solinas A; Taddei M; Ruat M
    Mol Pharmacol; 2011 Mar; 79(3):453-60. PubMed ID: 21177415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
    Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
    Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
    Peluso MO; Campbell VT; Harari JA; Tibbitts TT; Proctor JL; Whitebread N; Conley JM; White KF; Kutok JL; Read MA; McGovern K; Faia KL
    PLoS One; 2014; 9(3):e90534. PubMed ID: 24608250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
    Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
    FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family as smoothened antagonists.
    Manetti F; Faure H; Roudaut H; Gorojankina T; Traiffort E; Schoenfelder A; Mann A; Solinas A; Taddei M; Ruat M
    Mol Pharmacol; 2010 Oct; 78(4):658-65. PubMed ID: 20664000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
    Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
    Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
    Bhattarai D; Jung JH; Han S; Lee H; Oh SJ; Ko HW; Lee K
    Eur J Med Chem; 2017 Jan; 125():1036-1050. PubMed ID: 27810591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaffold hopping approach to a new series of smoothened antagonists.
    Lu W; Geng D; Sun Z; Yang Z; Ma H; Zheng J; Zhang X
    Bioorg Med Chem Lett; 2014 May; 24(10):2300-4. PubMed ID: 24726807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer.
    Espinosa-Bustos C; Bertrand J; Villegas-Menares A; Guerrero S; Di Marcotullio L; Navacci S; Schulte G; Kozielewicz P; Bloch N; Villela V; Paulino M; Kogan MJ; Cantero J; Salas CO
    Bioorg Chem; 2024 Oct; 151():107681. PubMed ID: 39106711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrvinium attenuates Hedgehog signaling downstream of smoothened.
    Li B; Fei DL; Flaveny CA; Dahmane N; Baubet V; Wang Z; Bai F; Pei XH; Rodriguez-Blanco J; Hang B; Orton D; Han L; Wang B; Capobianco AJ; Lee E; Robbins DJ
    Cancer Res; 2014 Sep; 74(17):4811-21. PubMed ID: 24994715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
    Pietrobono S; Stecca B
    Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.